Dr. Nicholas Murray Donin, MD

Dr. Donin practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Donin's NPI, 1780902015, was assigned on May 11, 2010. Dr. Donin graduated from Vagelos College of Physicians and Surgeons in 2010. Dr. Donin holds California license A135232.

Dr. Donin's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Donin's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Donin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Donin to 4 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Donin practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Donin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Donin is board certified in urology by the American Board of Urology. Dr. Donin is licensed in California.

Dmand AI lists bladder disease, bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Donin treats.

CMS data shows 1,530 Medicare services from Dr. Donin across 18 procedure codes in 2024, for 534 Medicare patients. Medicare paid $126,915 for them.

CMS counts 534 Medicare patients who saw Dr. Donin in 2024. The largest group is 65 to 74, with 266 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Donin's median patient age at 71, with 9% women.

In 2024, Dr. Donin wrote 1,531 Medicare Part D claims for 464 patients. 87% of them were for generic drugs. CMS names the drug for 1,367 of them, across 24 drugs with 11 or more claims each, at $206,777 in total drug cost. In 2023, CMS named 1,053 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Donin for performance year 2024, reported as part of a group. Dr. Donin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Donin as offering telehealth. CMS counts 42 procedures of prostate resection by Dr. Donin, more than 96% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 39 papers to Dr. Donin, published from 2011 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Kidney Neoplasms, Neoplasm Grading and Postoperative Complications. Dr. Donin has published most often in Clin Genitourin Cancer. Dr. Donin's most frequent co-authors are Karim Chamie, MD, Allan Pantuck, MD and Arie Belldegrun, MD.

CMS Open Payments shows 46 general payments to Dr. Donin from 20 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 60% of the total. Telix Pharmaceuticals paid the most, $15,600.

Dr. Donin serves on Robotic Surgical Curriculum Committee.

Dr. Donin graduated from Vagelos College of Physicians and Surgeons in 2010. Dr. Donin is a member of American Urological Association and Society of Urologic Oncology.

Dr. Donin is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.